75 citations
,
September 1971 in “British Journal of Dermatology” Both steroids effectively promote hair growth for at least 9 months.
January 2023 in “National journal of physiology, pharmacy and pharmacology” Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
July 1996 in “Clinical and Experimental Dermatology” Putting calcipotriol ointment on the skin once doesn't change calcium levels in the body right away.
1 citations
,
October 2023 in “Journal of the Endocrine Society” HIV medication ritonavir can increase the effects of nasal sprays like fluticasone, causing Cushing's syndrome.
1 citations
,
February 2024 in “JEADV Clinical Practice” Pulse corticosteroid therapy helps many with severe alopecia areata regrow hair, but has side effects.
2 citations
,
January 2018 in “International journal of research in dermatology” Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
2 citations
,
November 1996 in “Transplantation” Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.
284 citations
,
November 1999 in “Neurology” The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.
1 citations
,
August 2005 in “British Journal of Dermatology” Accidentally eating a topical steroid may rarely cause acute generalized pustular psoriasis.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
July 2025 in “International Journal of Trichology” Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
December 2024 in “International Journal For Multidisciplinary Research” Topical creams are commonly used for treating non-infective skin diseases in children, with antifungals being the most prescribed.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
1 citations
,
December 2025 in “Journal of the American Academy of Dermatology”
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
25 citations
,
January 1978 in “JAMA” Topical corticosteroids can cause serious side effects like Cushing's syndrome and hirsutism.
January 2026 in “Microorganisms” Bifidobacterium animalis subsp. lactis J12 helps reduce atopic dermatitis symptoms.
July 2022 in “British Journal of Dermatology”
9 citations
,
June 2013 in “Australasian Journal of Dermatology” Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.
55 citations
,
January 1988 in “Dermatology” Diphencyprone treatment for alopecia areata can cause vitiligo in some patients.
March 2021 in “Arrow - TU Dublin (Technological University Dublin)” The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
10 citations
,
January 2018 in “International Journal of Trichology” Mesalazine may help treat extensive alopecia areata effectively.
July 2020 in “CRS 2020 Virtual Annual Meeting” Researchers developed a new skin patch that delivers more finasteride into the skin, potentially improving treatment for hair loss and prostate issues.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
14 citations
,
February 2013 in “PubMed” Patients treated with long-term intralesional corticosteroids for alopecia areata should be monitored for bone density changes and advised on osteoporosis prevention.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.